Tolebrutinib Phase 3 Studies Published, Supporting Review by FDA for Treating Nonrelapsing Secondary Progressive MS
April 11, 2025
April 11, 2025
NEW YORK, April 11 -- The National Multiple Sclerosis Society issued the following news on April 10, 2025:
* * *
Tolebrutinib Phase 3 Studies Published, Supporting Review by FDA for Treating Nonrelapsing Secondary Progressive MS
The phase 3 studies of oral BTK-inhibitor tolebrutinib have been published in The New England Journal of Medicine. The results provide evidence for tolebrutinib as an effective treatment for nonrelapsing secondary progressive MS* - . . .
* * *
Tolebrutinib Phase 3 Studies Published, Supporting Review by FDA for Treating Nonrelapsing Secondary Progressive MS
The phase 3 studies of oral BTK-inhibitor tolebrutinib have been published in The New England Journal of Medicine. The results provide evidence for tolebrutinib as an effective treatment for nonrelapsing secondary progressive MS* - . . .